X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MNPR-101-Zr is a radioactive large molecule drug candidate, which is currently being evaluated for the treatment of uPAR-expressing triple-negative breast cancer.
Lead Product(s): MNPR-101-Zr
Therapeutic Area: Oncology Product Name: MNPR-101-Zr
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
MNPR-101-Zr is a zirconium-89 labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly selective against uPAR. It is being developed for the treatment of triple-negative breast, colorectal, & pancreatic cancers.
Lead Product(s): MNPR-101-Zr
Therapeutic Area: Oncology Product Name: MNPR-101-Zr
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: North Star Processing, LLC.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
MNPR-101-Zr is a zirconium-89 labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly selective against uPAR. It is being developed for the treatment of triple-negative breast, colorectal, & pancreatic cancers.
Lead Product(s): MNPR-101-Zr
Therapeutic Area: Oncology Product Name: MNPR-101-Zr
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
MNPR-201 (camsirubicin) is a novel proprietary analog of widely used cancer drug doxorubicin. Doxorubicin is used to treat adult and pediatric solid and hematologic cancers including breast, gastric, ovarian and bladder cancer, soft tissue sarcomas, leukemias and lymphomas.
Lead Product(s): Camsirubicin,Pegfilgrastim
Therapeutic Area: Oncology Product Name: MNPR-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
The collaboration aims to evaluate radiopharmaceutical versions of MNPR-101 RIT in several aggressive cancers. MNPR-101 is a novel, first-in-class humanized monoclonal antibody to the urokinase Plasminogen Activator Receptor (uPAR).
Lead Product(s): MNPR-101,Actinium-225
Therapeutic Area: Oncology Product Name: MNPR-101 RIT
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cancer Science Institute of Singapore
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 11, 2023
Details:
Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Doxorubicin is used to treat adult and pediatric solid and hematologic cancers including breast, gastric, ovarian and bladder cancer, soft tissue sarcomas, leukemias and lymphomas.
Lead Product(s): Camsirubicin,Pegfilgrastim
Therapeutic Area: Oncology Product Name: MNPR-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
Validive® (clonidine hydrochloride) is a novel mucobuccal tablet formulation, indiacted for oropharyngeal cancer. It agonizes the alpha-2 adrenergic receptor on macrophages, decreasing the release of the destructive cytokines that are produced in response to radiotherapy.
Lead Product(s): Clonidine
Therapeutic Area: Immunology Product Name: Validive
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
Camsirubicin is a novel, proprietary analog of the widely used cancer drug doxorubicin. The current Phase 1b trial is designed to test camsirubicin at progressively higher doses than previously administered while using concomitant prophylactic G-CSF to prevent neutropenia.
Lead Product(s): Camsirubicin,Pegfilgrastim
Therapeutic Area: Oncology Product Name: MNPR-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Camsirubicin is a novel, proprietary analog of the widely used cancer drug doxorubicin. The current Phase 1b trial is designed to test camsirubicin at progressively higher doses than previously administered while using concomitant prophylactic G-CSF to prevent neutropenia.
Lead Product(s): Camsirubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
MNPR-202 is a promising DNA Damaging Response (DDR) drug candidate, and analog of doxorubicin. It has the same potentially non-cardiotoxic backbone as camsirubicin.
Lead Product(s): MNPR-202
Therapeutic Area: Oncology Product Name: MNPR-202
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Science Institute of Singapore
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
